The Level of vWF Antigen and Coagulation Markers in Hospitalized Patients with Covid-19

References

• Zhu N, Zhang D, Wang W, et al.; China Novel Coronavirus Investigating and Research Team. A novel coronavirus from patients with pneumonia in China, 2019. N Engle J Med. 2020;382(8):727–733. doi:10.1056/NEJMoa2001017
   PubMed Web of Science ®Google Scholar
• Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese center for disease control and prevention. JAMA. 2020;323(13):1239. doi:10.1001/jama.2020.2648
   PubMed Web of Science ®Google Scholar
• World Health Organization. A novel coronavirus (2019-nCoV). Situation report - 1. 2020.
   Google Scholar
• World Health Organization. B Coronavirus disease 2019 (COVID-19). Situation report – 51. 2020.
   Google Scholar
• World Health Organization. Coronavirus disease (COVID-19) weekly epidemiological update and weekly operational update. March. 2021.
   Google Scholar
• Weqaya A. COVID-19-19 Daily Update of Cases. Riyadh, Saudi Arabia: Weqaya-Saudi Center for Disease Control and Prevention; 2021.
   Google Scholar
• Klok FA, Kruip MJHA, van der Meer NJM, et al. Incidence of thrombotic complications in critically ill ICU patients with COVID-19. Thromb Res. 2020;191:145–147. doi:10.1016/j.thromres.2020.04.013
   PubMed Web of Science ®Google Scholar
• Cui S, Chen S, Li X, Liu S, Wang F. Prevalence of venous thromboembolism in patients with severe novel coronavirus pneumonia. J Thromb Haemost. 2020;18(6):1421–1424. PMID: 32271988. doi:10.1111/jth.14830
   PubMed Web of Science ®Google Scholar
• Llitjos JF, Leclerc M, Chochois C, et al. High incidence of venous thromboembolic events in anticoagulated severe COVID-19 patients. J Thromb Haemost. 2020;22(10):1111.
   Google Scholar
• Lodigiani C, Iapichino G, Carenzo L, et al. Humanitas COVID-19 task force. Venous and arterial thromboembolic complications in COVID-19 patients admitted to an academic hospital in Milan, Italy. Thromb Res. 2020;191:9–14. PMID: 32353746. doi:10.1016/j.thromres.2020.04.024
   PubMed Web of Science ®Google Scholar
• Wichmann D, Sperhake JP, Lütgehetmann M, Steurer S, Edler C, Heinemann A. Autopsy findings and venous thromboembolism in patients with COVID-19. Ann Intern Med. 2020:M20–2003. PMID: 32374815.
   Google Scholar
• Mucha SR, Dugar S, McCrae K, et al. Coagulopathy in COVID-19. Cleve Clin J Med. 2020. PMID: 3240943.
   Web of Science ®Google Scholar
• Becker RC. COVID-19 update: COVID-19-associated coagulopathy. J Thromb Thrombolysis. 2020;50(1):54–67. PMID: 32415579. doi:10.1007/s11239-020-02134-3
   PubMed Web of Science ®Google Scholar
• Görlinger K, Dirkmann D, Gandhi A, Simioni P. COVID-19-associated coagulopathy and inflammatory response: what do we know already and what are the knowledge gaps? Anesth Analg. 2020;131(5):1324–1333. PMID: 33079850; PMCID: PMC7389937. doi:10.1213/ANE.0000000000005147
   Web of Science ®Google Scholar
• Tang N, Li D, Wang X, Sun Z. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J Thromb Haemost. 2020;18(4):844–847. doi:10.1111/jth.14768
   PubMed Web of Science ®Google Scholar
• Levi M, Jonge E, van der Poll T. de Sepsis and disseminated intravascular coagulation. J Thromb Thrombolysis. 2003;16(1/2):43–47. doi:10.1023/B:THRO.0000014592.27892.11
   PubMed Web of Science ®Google Scholar
• Callaway E, Ledford H, Mallapaty S. Six months of coronavirus: the mysteries scientists are still racing to solve. Nature. 2020;583(9):178–179. doi:10.1038/d41586-020-01989-z
   Web of Science ®Google Scholar
• Shalhub S. The mystery of COVID-19-associated arterial thrombosis. J Vasc Surg. 2021;73(2):390–391. doi:10.1016/j.jvs.2020.08.022
   Web of Science ®Google Scholar
• Metlay JP, Waterer GW, Long AC, Anzueto A, Brozek J. Diagnosis and treatment of adults with community-acquired pneumonia. an official clinical practice guideline of the American Thoracic Society and Infectious Diseases Society of America. Am J Respir Crit Care Med. 2019;200(7).
   Web of Science ®Google Scholar
• Escher R, Breakey N, Lämmle B. Severe COVID-19 infection associated with endothelial activation. Thromb Res. 2020;190:62. doi:10.1016/j.thromres.2020.04.014
   PubMed Web of Science ®Google Scholar
• Levi M, van der Poll T. Inflammation and coagulation. Crit Care Med. 2010;38(2 Suppl):S26–34. doi:10.1097/CCM.0b013e3181c98d21
   PubMed Web of Science ®Google Scholar
• Abou-Ismail MY, Diamond A, Kapoor S, Arafah Y, Nayak L. The hypercoagulable state in COVID-19: incidence, pathophysiology, and management. Thromb Res. 2020;194:101–115. doi:10.1016/j.thromres.2020.06.029
   PubMed Web of Science ®Google Scholar
• Ward SE, Curley GF, Lavin M; Irish COVID-19 Vasculopathy Study (ICVS) Investigators. Von Willebrand factor propeptide in severe coronavirus disease 2019 (COVID-19): evidence of acute and sustained endothelial cell activation. Br J Haematol. 2020;16. PMID: 33326604. doi:10.1111/bjh.17273
   Web of Science ®Google Scholar
• Elsoukkary S, Mostyka S, Dillard A. Autopsy findings in 32 patients with COVID-19: a single-institution experience. Pathobiology. 2021;88(1):56–68. doi:10.1159/000511325
   Web of Science ®Google Scholar
• Gao Y, Li T, Han M, et al. Diagnostic utility of clinical laboratory data determinations for patients with the severe COVID-19. J Med Virol. 2020;92(7):791–796. doi:10.1002/jmv.25770
   PubMed Web of Science ®Google Scholar
• Zhang L, Yan X, Fan Q, et al. D-dimer levels on admission to predict in-hospital mortality in patients with COVID-19. J Thromb Haemost. 2020;18(6):1324–1329. doi:10.1111/jth.14859
   PubMed Web of Science ®Google Scholar
• Stief TW, Ijagha O, Weiste B, Herzum I, Renz H, Max M. Analysis of hemostasis alterations in sepsis. Blood Coagul Fibrinolysis. 2007;18(2):179–186. doi:10.1097/MBC.0b013e328040bf9a
   Web of Science ®Google Scholar
• Scarlatescu E, Lance MD. Lance Crimean-Congo haemorrhagic fever: test early with ROTEM? Lancet Infect Dis. 2019;19(8):796–797. doi:10.1016/S1473-3099(19)30298-1
   Web of Science ®Google Scholar
• Wang D, Hu B, Hu C, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan China. JAMA. 2020;323(11):1061–1069. doi:10.1001/jama.2020.1585
   PubMed Web of Science ®Google Scholar
• Henry BM. COVID-19, ECMO, and lymphopenia: a word of caution. Lancet Respir Med. 2020;8(4):e24. doi:10.1016/S2213-2600(20)30119-3
   Web of Science ®Google Scholar
• Shang J, Wan Y, Luo C, et al. Cell entry mechanisms of SARS-CoV-2. Proc Natl Acad Sci U S A. 2020;117(21):11727–11734. doi:10.1073/pnas.2003138117
   PubMed Web of Science ®Google Scholar
• Brojakowska A, Narula J, Shimony R, Bander J. Clinical implications of SARS-CoV-2 interaction with renin angiotensin system: JACC review topic of the week. J Am Coll Cardiol. 2020;75(24):3085–3095. doi:10.1016/j.jacc.2020.04.028
   PubMed Web of Science ®Google Scholar
• Matarese A, Gambardella J, Sardu C, Santulli G. miR-98 regulates TMPRSS2 expression in human endothelial cells: key implications for COVID-19. Biomedicines. 2020;8(11):462. doi:10.3390/biomedicines8110462
   PubMed Web of Science ®Google Scholar
• Glowacka I, Bertram S, Muller MA, et al. Evidence that TMPRSS2 activates the severe acute respiratory syndrome coronavirus spike protein for membrane fusion and reduces viral control by the humoral immune response. J Virol. 2011;85(9):4122–4134. doi:10.1128/JVI.02232-10
   PubMed Web of Science ®Google Scholar
• D’Onofrio N, Scisciola L, Sardu C, et al. Glycated ACE2 receptor in diabetes: open door for SARS-COV-2 entry in cardiomyocyte. Cardiovasc Diabetol. 2021;20(1):99. PMID: 33962629; PMCID: PMC8104461. doi:10.1186/s12933-021-01286-7
   PubMed Web of Science ®Google Scholar
• Sardu C, Gargiulo G, Esposito G, et al. Impact of diabetes mellitus on clinical outcomes in patients affected by Covid-19. Cardiovasc Diabetol. 2020;19(1):76. doi:10.1186/s12933-020-01047-y
   PubMed Web of Science ®Google Scholar
• Sardu C, Maggi P, Messina V, et al. Could anti-hypertensive drug therapy affect the clinical prognosis of hypertensive patients with COVID-19 infection? Data from centers of southern Italy. J Am Heart Assoc. 2020;9(17):e016948. Epub 2020 Jul 7. PMID: 32633594; PMCID: PMC7660768. doi:10.1161/JAHA.120.016948
   PubMed Web of Science ®Google Scholar
• Sardu C, Marfella R, Maggi P, et al. Implications of AB0 blood group in hypertensive patients with covid-19. BMC Cardiovasc Disord. 2020;20(1):373. doi:10.1186/s12872-020-01658-z
   PubMed Web of Science ®Google Scholar
• López Reboiro ML, Suárez Fuentetaja R, Gutiérrez López R, et al. Role of lupus anticoagulant and von Willebrand factor in chronic reactive endotheliitis in COVID-19. J Infect. 2021;82(6):e27–e28. Epub 2021 Mar 15. PMID: 33737115; PMCID: PMC7959681. doi:10.1016/j.jinf.2021.03.006
   PubMed Web of Science ®Google Scholar